Triple-Drug cocktail shows promise for First-Line CLL treatment
NCT ID NCT03580928
First seen Feb 14, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This study tests a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) as an initial treatment for people with chronic lymphocytic leukemia (CLL) who have not had prior therapy. The goal is to see if this combination can clear leukemia cells from the bone marrow. The study includes a group of patients with a specific genetic abnormality (TP53 mutation).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut, 06904, United States
Conditions
Explore the condition pages connected to this study.